Canadian-Led Immunotherapies in Cancer (CLIC)

Dr. Natasha Kekre
“Canadian patients deserve access to the best cancer treatments in the world, and we need Canadian research to make this happen,” said Dr. Natasha Kekre of The Ottawa Hospital.

The CLIC research program, established in 2016, brings researchers, clinicians and patients from across Canada together to build Canadian expertise and capacity for innovation in the promising field of cellular immunotherapy for cancer, including CAR-T therapy.

Cellular immunotherapies such as CAR-T cell therapy have shown great promise in treating certain kinds of blood cancer and have potential in treating other cancers as well. CAR-T therapy involves extracting immune cells called T cells from a patient, genetically engineered them to enhance their cancer-killing ability, and then giving them back to the same patient.

“We are delighted to work with partners across Canada to build Canadian expertise, capacity for innovation, and clinical trials in this field,” said Dr. Kevin Hay of BC Cancer.

The first CLIC clinical trial launched in 2019 at The Ottawa Hospital and at BC Cancer and is showing promising preliminary results. The trial is the first to manufacture CAR-T therapy in Canada.

While Health Canada has approved several commercial CAR-T therapies, access is restricted to people with just a few kinds of leukemia and lymphoma, and only if they fall into certain age ranges. Commercial CAR-T therapy is also very expensive and involves shipping cells to the United States and back.

CLIC uses a different kind of cell manufacturing that opens the door to less expensive and more equitable CAR-T treatment across Canada. It also provides a platform for the development of even better cellular immunotherapies that may work for more kinds of cancer.


Funding partners

  • BioCanRx
  • BC Cancer
  • The Ottawa Hospital Foundation
  • BC Cancer Foundation
  • Ontario Institute for Cancer Research
  • Ottawa Regional Cancer Foundation
  • Leukemia and Lymphoma Society of Canada
  • Canadian Institutes of Health Research

Core facilities and supporting resources


CAR-T clinical trial provides ‘one last shot’ for leukemia patient
January 11, 2023 - Camille Leahy was out of options. Here's what led her to a Canadian-first CAR T-cell therapy clinical trial at our hospital.
Canadian-Led Immunotherapies in Cancer (CLIC) program inspires innovative CAR-T trial in Denmark
December 8, 2022 - CAR-T therapy is a groundbreaking cancer treatment that involves genetically engineering a patient’s own immune cells to attack their cancer. While this therapy is commercially available in many countries, cancer researchers are also developing their
First made-in-Canada CAR-T cell therapy for cancer shows promise in clinical trial
June 17, 2022 - More than a dozen people with cancer who had exhausted all treatment options are alive and cancer-free today thanks to a pioneering Canadian clinical trial of a highly personalized kind of immunotherapy.
Show more news stories